Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The precursor B cell receptor (pre-BCR) is a transmembrane protein complex expressed during early B cell development. It is composed of the Ig heavy chain paired with a surrogate light chain (VpreB and λ5 components) and associated with signaling subunits Igα and Igβ[1][2]. Its assembly marks a critical checkpoint: only B cells with successfully rearranged heavy chains proceed to light chain recombination. Pre-BCR signaling drives proliferation, allelic exclusion, and differentiation, influencing the emerging B cell repertoire[1][2]. In the context of "germline B cell receptor precursor targeting," this refers not to a molecule but to an approach (not a classical target) whereby vaccines are engineered to bind and activate naïve, germline-encoded BCRs as the initial step to elicit a desired antibody response, such as in HIV vaccine design[6]. There is no standard abbreviation or therapeutic agent that targets "germline B cell receptor precursor" as a molecule; rather, the phrase describes immunogen design strategies aiming to engage unmutated (germline) BCRs[6].
Engagement of germline BCRs to guide immune maturation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Precursor B cell receptor (pre-BCR).